Sobi Announces Launch of the INTO-HLH Registry, a Disease Registry for Patients with Hemophagocytic Lymphohistiocytosis (HLH)

3 years ago

INTO-HLH Registry serves as the first in-depth disease registry for the HLH medical and patient community in North AmericaWALTHAM, Mass.,…

Petalfast Partners with Turning Point Brands to Expand Distribution of Zig-Zag

3 years ago

The iconic rolling paper brand joins Petalfast’s growing alternative consumer products portfolio in CaliforniaIRVINE, Calif., June 28, 2022 (GLOBE NEWSWIRE)…

Panbela Announces Publication of Preclinical Data Titled: Expanded Potential of the Polyamine Analogue SBP-101 (Diethyl Dihydroxyhomospermine) as a Modulator of Polyamine Metabolism and Cancer Therapeutic

3 years ago

In vitro studies determined that SBP-101 reduced cellular viability across a broad range of cancer cell types, with an exceptionally…

G1 Therapeutics Announces Addition of Jacks Lee to Board of Directors

3 years ago

RESEARCH TRIANGLE PARK, N.C., June 28, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today…

Verrica Pharmaceuticals Holds Type A Meeting with FDA for VP-102 for Molluscum Contagiosum

3 years ago

WEST CHESTER, Pa., June 28, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing…

Graybug Announces Review of Strategic Alternatives

3 years ago

BALTIMORE, June 28, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative…

Fate Therapeutics Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceutical for Off-the-Shelf, iPSC-derived CAR NK and CAR T-Cell Cancer Immunotherapies

3 years ago

ONO to Contribute Novel Binding Domains for a Second Solid Tumor Antigen to the Collaboration Expanded Partnership Enables Development of…

EnGeneIC’s second generation COVID-19 vaccine protects against all variants

3 years ago

SYDNEY, Australia, June 28, 2022 (GLOBE NEWSWIRE) -- The world’s first COVID-19 vaccine to offer immunity against all variants is…

Theralase Expands Intellectual Property Portfolio

3 years ago

TORONTO, June 28, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical…

Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy

3 years ago

- 87% of patients who experienced ototoxicity in their placebo-treated ear were protected from ototoxicity in their DB-020-treated ear –…